Comparing MSCI (NYSE:MSCI) and BR Biopharma (NASDAQ:BRBI)

MSCI (NYSE:MSCI) and BR Biopharma (NASDAQ:BRBI) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Institutional and Insider Ownership

90.0% of MSCI shares are owned by institutional investors. 3.8% of MSCI shares are owned by insiders. Comparatively, 29.4% of BR Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent ratings for MSCI and BR Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MSCI	0	0	11	1	3.08
BR Biopharma	1	0	0	0	1.00

MSCI presently has a consensus price target of $709.50, suggesting a potential upside of 27.82%. Given MSCI’s stronger consensus rating and higher possible upside, equities analysts clearly believe MSCI is more favorable than BR Biopharma.

Dividends

MSCI pays an annual dividend of $8.20 per share and has a dividend yield of 1.5%. BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.7%. MSCI pays out 44.9% of its earnings in the form of a dividend. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. MSCI has increased its dividend for 11 consecutive years.

Earnings & Valuation

This table compares MSCI and BR Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MSCI	$3.13 billion	12.87	$1.20 billion	$18.28	30.36
BR Biopharma	$2.23 billion	0.06	$31.36 million	$0.08	140.26

MSCI has higher revenue and earnings than BR Biopharma. MSCI is trading at a lower price-to-earnings ratio than BR Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MSCI and BR Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MSCI	40.74%	-55.19%	24.90%
BR Biopharma	N/A	N/A	N/A

Summary

MSCI beats BR Biopharma on 13 of the 17 factors compared between the two stocks.

About MSCI

MSCI Inc., together with its subsidiaries, provides critical decision support tools and solutions for the investment community to manage investment processes worldwide. The Index segment provides indexes for use in various areas of the investment process, including indexed financial product, such as ETFs, mutual funds, annuities, futures, options, structured products, and over-the-counter derivatives; performance benchmarking; portfolio construction and rebalancing; and asset allocation, as well as licenses GICS and GICS Direct. The Analytics segment offers risk management, performance attribution and portfolio management content, application, an integrated view of risk and return service, and an analysis of market, credit, liquidity, counterparty, and climate risk across asset classes; managed services, including consolidation of client portfolio data, review and reconciliation of input data and results, and customized reporting; and HedgePlatform to measure, evaluate, and monitor the risk of hedge fund investments. The ESG and Climate segment provides products and services that help institutional investors understand how ESG impacts the long-term risk and return of their portfolio and individual security-level investments; and data, ratings, research, and tools to help investors navigate increasing regulation. The All Other Private Assets segment includes real estate and infrastructure data, benchmarks, return-analytics, climate assessments and market insights; business intelligence to real estate owners, managers, developers, and brokers; and offers investment decision support tools for private capital. The Private Capital Solutions segment offers tools to help private asset investors across mission-critical workflows, such as sourcing terms and conditions, evaluating operating performance, managing risk and other activities supporting private capital investing. MSCI Inc. was incorporated in 1998 and is headquartered in New York, New York.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.